WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that Michael D. Taylor, Ph.D., Deciphera’s President and Chief Executive Officer will present a corporate update at the JMP Securities Life Sciences Conference on Tuesday, June 23, 2015 at 10:00 a.m. ET in New York.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals seeks to improve treatment for patients with cancer by designing kinase inhibitor therapies that target the hallmarks of cancer biology. We specifically design our small molecule compounds to simultaneously block multiple cancer signaling mechanisms in the tumor cell and the tumor microenvironment to prevent growth and spread. Deciphera’s unique approach represents an important advance over current therapies in the durability of kinase inhibition and resiliency to genetic mutations to provide greater benefit across a range of cancers. Deciphera’s business strategy is to advance its drug candidates for genetically defined cancers and cancers that target the tumor microenvironment through both proprietary and partnered programs.
Deciphera’s internal product pipeline includes altiratinib, a MET/TIE2/TRK/VEGFR2 kinase inhibitor currently in Phase 1 clinical development, a pan-KIT inhibitor (DCC-2618) currently in preclinical development and rebastinib, a TIE2 kinase inhibitor currently in Phase 1 clinical development. Our ultra-specific FMS inhibitor (DCC-3014), which blocks the actions of pro-tumoral macrophages in the tumor microenvironment, is currently in preclinical development. In addition, a pan-RAF inhibitor is currently in Phase 1 development with Lilly.